Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1366644
PUBLISHER: FirstWord Group | PRODUCT CODE: 1366644
Ankylosing Spondylitis - KOL Insight
PUBLISHED: annual subscription
PAGES:
DELIVERY TIME:
SELECT AN OPTION
What does the future AS therapy landscape look like? Will the domination of anti-TNFs continue? How do KOLs assess the potential of anti-IL17 strategies? Could a re-evaluation of safety concerns see wider use of JAK inhibitors such as AbbVie's Rinvoq and Pfizer's Xeljanz? What pipeline therapies could bring new treatment options? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to KOL Bulletins.
Table of Contents
Executive summary (8)
Treatment algorithm (1)
Research objectives (5)
TNF inhibitors (12)
- Marketed therapies (12)
- Remicade (infliximab; Janssen Biotech/Merck & Co.); Enbrel (etanercept; Pfizer/Amgen); Simponi (golimumab; Janssen Biotech/Merck & Co.); Humira (adalimumab; AbbVie); Cimzia (certolizumab pegol; UCB) (12)
IL-17 inhibitors (34)
- Approved therapies (28)
- Cosentyx (secukinumab; Novartis) (10)
- Taltz (ixekizumab; Lilly) (9)
- Bimzelx (bimekizumab; UCB) (9)
- Pipeline drugs (6)
- Izokibep (Acelyrin/Affibody) (6)
JAK inhibitors (18)
- Approved therapies (14)
- Rinvoq (upadacitinib; AbbVie) (8)
- Xeljanz (tofacitinib; Pfizer) (6)
- Pipeline therapies (4)
- Jyseleca (filgotinib; Galapagos NV) (4)
Other mechanisms of action (6)
- Pipeline therapies (6)
- Namilumab (Amgen/Takeda/Izana) (6)
Future treatment paradigm (11)
- Key insights summary (11)
Appendix (4)
- KOL details (4)
- KOLs from North America (1)
- KOLs from Europe (2)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.